查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856475

何傑金氏淋巴瘤（HL）治療市場按治療類型、分期、治療線數、分子類型和患者年齡分類－全球預測，2025-2032年

Hodgkin Lymphoma Treatment Market by Treatment Type, Disease Stage, Treatment Line, Molecule Type, Patient Age - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，何傑金氏淋巴瘤(HL) 治療市場將成長至 27.1 億美元，複合年成長率為 9.51%。

關鍵市場統計數據
基準年 2024 13.1億美元
預計年份：2025年 14.3億美元
預測年份 2032 27.1億美元
複合年成長率 (%) 9.51%

一份簡潔且全面的框架，闡述了不斷發展的何傑金氏淋巴瘤（HL）治療格局如何影響臨床、監管和商業性決策。

何傑金氏淋巴瘤(HL) 的治療已進入一個以治療創新、臨床實踐發展和監管預期變化為特徵的新時代。儘管化療和放射線治療等傳統治療方法仍然是多模式治療的重要組成部分，但免疫療法和標靶藥物的最新進展正在再形成臨床決策路徑。同時，對患者族群特徵和存活期的關注也推動著治療方法選擇和長期毒性管理的改進。

免疫療法、精準放射線治療和生物標記主導的臨床設計方面的突破性進展如何從根本上改變何傑金氏淋巴瘤(HL) 的治療路徑和相關人員的優先事項

何傑金氏淋巴瘤的治療格局正在經歷一場變革，這主要得益於科學突破、治療模式的演變以及以患者為中心的護理理念。針對免疫查核點的免疫療法藥物和抗體藥物複合體正在重新定義預期療效，並為過去僅接受細胞毒性藥物治療的患者開闢新的治療選擇。同時，放射治療技術的進步，包括自我調整計畫和質子束放射治療，與全身性治療相結合，正在降低繼發性毒性，並實現更精準的局部控制。

了解2025年美國貿易政策調整對何傑金氏淋巴瘤（HL）治療交付和產業策略的營運、供應鏈和進入影響。

美國將於2025年實施新的關稅政策，將對何傑金氏淋巴瘤（HL）治療生態系統產生多方面的影響，涉及商業物流、供應鏈韌性和准入等諸多方面。關稅調整可能會改變進口活性藥物原料藥以及放射治療和藥物生產中使用的專用設備的成本結構，迫使製造商重新評估籌資策略和供應商合約。這些營運方面的變化往往會引發一系列策略選擇，例如將供應鏈的部分環節遷回國內、實現供應商多元化以及談判長期採購協議以降低貿易政策波動帶來的風險。

基於深度細分的洞察，將治療方式、分期、分子分型、治療線數和患者年齡層與可操作的臨床和商業性意義聯繫起來。

深入的細分揭示了不同治療方式、疾病階段、治療線數、分子分型和患者年齡層之間截然不同的臨床和商業動態。依治療類型分析，可選擇的治療方案包括ABVD、BEACOPP等化療方案和脂質體製劑、免疫療法、放射線治療（包括自我調整計劃、受累野技術和質子療法）以及分子標靶療法。每種治療方法都有獨特的療效和毒性特徵，可為患者選擇和治療順序提供依據。

美洲、歐洲、中東和非洲以及亞太地區的臨床、監管和准入動態將影響區域策略和病患准入途徑。

區域動態影響美洲、歐洲、中東和非洲以及亞太地區的臨床實踐模式、監管時間表和准入策略。在美洲，整合的腫瘤學網路和已建立的臨床路徑促進了循證方案的快速應用，而報銷機制和與支付方的談判則決定了高成本生物製藥和先進放射治療技術的可及性。跨境合作和學術中心在臨床試驗註冊和轉化研究中也發揮著重要作用。

臨床產品組合、策略夥伴關係、供應鏈能力和實證醫學成果等因素塑造的競爭動態，將決定何傑金氏淋巴瘤（HL）治療領域的長期差異化優勢。

競爭格局呈現出多元化的特點，既有成熟的腫瘤治療公司，也有專注於抗體和小分子療法的生物技術公司，以及專注於放射腫瘤硬體和軟體的技術合作夥伴。主要企業憑藉其臨床產品組合、生物標記主導的研發能力、策略聯盟以及在監管和支付方環境中的經驗脫穎而出。除了產品平臺之外，各公司還透過投資生物製藥生產能力、全球供應鏈網路以及真實世界證據的產生來支撐其長期價值提案，從而實現差異化競爭。

為製造商和醫療服務提供者提供營運和策略建議，以協調臨床開發、供應鏈韌性和支付方參與，從而改善患者療效。

行業領導者應採取整合策略，協調臨床開發、商業策略和市場准入計劃，確保治療方案惠及最需要的患者。首先，應優先進行以生物標記主導的隊列研究和患者報告結局為指標的臨床項目，以證明治療效果超越了傳統的療效指標。這種策略將有助於加強監管和醫療保險報銷方面的討論，並支持重視持久緩解和生活品質的臨床醫生採納相關治療方案。

採用嚴謹的多源調查方法，結合文獻綜述、專家訪談和跨細分市場分析，得出可操作的臨床和商業性見解。

本調查方法採用多源方法，結合了系統性文獻綜述、專家訪談以及對監管和臨床實踐文件的定性分析。第一手資料包括同行評審的臨床研究、共識指南以及主要腫瘤學會的意見，這些文獻經過綜合分析，反映了目前的臨床實踐和治療原理。次要文獻來源包括臨床試驗註冊資訊、監管核准以及已發表的真實世界研究，這些研究為研究方法的應用和結果比較提供了背景資訊。

整合臨床創新、業務需求和策略重點，以明確何傑金氏淋巴瘤(HL) 治療和醫療服務取得的未來方向。

總之，何傑金氏淋巴瘤(HL) 的治療格局呈現出顯著的臨床創新、不斷發展的治療標準以及複雜的運作考量等特點，這些因素共同影響著患者的治療機會和治療策略。新型免疫療法和標靶分子正在重塑臨床治療手段，而放射療法的進步則在降低毒性的同時，拓展了局部疾病控制的選擇。為了最佳化不同族群的治療效果，必須綜合考慮疾病分期、治療線數、分子分型和患者年齡等因素，全面評估這些臨床進展。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將PD-1查核點抑制劑整合到難治性何傑金氏淋巴瘤患者的第一線治療通訊協定中
  • 在復發或難治性何傑金氏淋巴瘤患者中誘導CD30靶向CAR-T細胞療法
  • 循環腫瘤DNA檢測在監測何傑金氏淋巴瘤（HL）微量殘存疾病和指南治療的新興作用
  • 生物相似藥布倫妥昔單抗（brentuximab vedotin）上市對晚期何傑金氏淋巴瘤治療定價與可近性的影響
  • 擴大真實世界證據研究在評估何傑金氏淋巴瘤（HL）倖存者長期安全性結果的應用
  • 開發靶向 PD-1 和 CD30 的雙特異性抗體以增強何傑金氏淋巴瘤(HL) 的免疫療法療效
  • 在復發性何傑金氏淋巴瘤患者中擴大查核點抑制劑和挽救化療的組合方案

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章何傑金氏淋巴瘤（HL）治療市場（按治療類型分類）

  • 化療
    • ABVD療法
    • 貝科普療法
    • 脂質體配方
  • 免疫療法
  • 放射線治療
    • 自我調整放射線治療
    • 受累野放射線治療
    • 質子治療
  • 標靶治療

第9章何傑金氏淋巴瘤（HL）治療市場依疾病分期分類

  • 晚期
    • 第三階段
    • 第四階段
  • 早期的
    • 第一階段
    • 第二階段

第10章何傑金氏淋巴瘤（HL）治療市場（依治療線分類）

  • 首選藥物
  • 二線藥物
  • 三線藥物

第11章何傑金氏淋巴瘤（HL）治療市場（按分子類型分類）

  • 單株抗體
    • CD30標靶抗體
      • 維布妥昔單抗
      • 新一代抗體
    • PD-1抑制劑
      • Nivolumab
      • Pembrolizumab
  • 低分子化合物
    • 組蛋白去乙醯化酶抑制劑
      • 下一代 HDAC 抑制劑
      • 羅米地辛
      • 沃里諾斯塔特

第12章何傑金氏淋巴瘤（HL）治療市場（依病患年齡分類）

  • 成人
  • 老年人
  • 兒童

第13章何傑金氏淋巴瘤（HL）治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章何傑金氏淋巴瘤（HL）治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國何傑金氏淋巴瘤（HL）治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Takeda Pharmaceutical Company Limited
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • Gilead Sciences, Inc.
    • Novartis AG
    • Roche Holding AG
    • Johnson & Johnson
    • Pfizer Inc.
    • Seagen Inc.
    • Kite Pharma, Inc.
Product Code: MRR-742BD517F76D

The Hodgkin Lymphoma Treatment Market is projected to grow by USD 2.71 billion at a CAGR of 9.51% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.31 billion
Estimated Year [2025] USD 1.43 billion
Forecast Year [2032] USD 2.71 billion
CAGR (%) 9.51%

A concise yet comprehensive framing of the evolving Hodgkin lymphoma treatment environment that shapes clinical, regulatory, and commercial decision-making

Hodgkin lymphoma treatment has entered an era marked by converging therapeutic innovation, evolving clinical practice, and shifting regulatory expectations. Recent advances in immunotherapy and targeted agents are reshaping clinical decision pathways while established modalities such as chemotherapy and radiotherapy remain integral to multidisciplinary care. At the same time, patient demographics and survivorship concerns are driving refinements in treatment selection and long-term toxicity management.

This introduction frames the landscape by outlining the interplay between novel agents and legacy treatments that together define contemporary therapeutic choices. It also highlights the importance of integrating disease staging and line of therapy considerations into clinical strategies, as these parameters influence eligibility for specific modalities and sequencing decisions. Moreover, greater emphasis on molecular characterization and biomarker-driven approaches is enabling more precise patient stratification, which in turn affects clinical trial design and real-world prescribing.

As stakeholders navigate this complex environment, they must balance efficacy, safety, and quality-of-life outcomes across adult, geriatric, and pediatric populations. In the following sections, the report examines transformative shifts, regulatory and policy influences including tariff dynamics, segmentation insights, and regional and competitive landscapes to provide a cohesive foundation for strategic decision-making and operational planning.

How breakthroughs in immunotherapy, precision radiotherapy, and biomarker-driven clinical designs are fundamentally reshaping Hodgkin lymphoma care pathways and stakeholder priorities

The Hodgkin lymphoma landscape is undergoing transformative shifts driven by scientific breakthroughs, evolving therapeutic paradigms, and patient-centered care priorities. Immunotherapy agents that engage the immune checkpoint and antibody-drug conjugate modalities are redefining response expectations and creating new options for patients who were historically treated with cytotoxic regimens alone. Concurrently, advances in radiotherapy, including adaptive planning and proton delivery, are reducing collateral toxicity and enabling more precise local control when combined with systemic therapies.

Translational science is accelerating the identification of biomarkers that inform patient selection and optimize therapeutic sequencing. As a result, clinical trial designs are progressively more adaptive, incorporating biomarker-enriched cohorts and novel endpoints that reflect durable responses and long-term survivorship. This shift toward personalized regimens is complemented by improvements in supportive care, which mitigate acute and late adverse events and facilitate outpatient treatment delivery.

Operationally, stakeholders must respond to changing reimbursement frameworks and payer expectations that increasingly value real-world evidence and long-term outcomes. In practice, multidisciplinary collaboration among hematologists, radiation oncologists, and allied specialists is becoming the cornerstone of care pathways. Consequently, organizations that align product development, clinical programs, and commercial strategies with these transformative trends will be positioned to deliver meaningful value to patients and providers.

Understanding the operational, supply chain, and access implications of U.S. trade policy adjustments in 2025 for Hodgkin lymphoma treatment delivery and industrial strategy

The introduction of new tariff policies in the United States for 2025 presents multifaceted implications for the Hodgkin lymphoma treatment ecosystem, touching commercial logistics, supply chain resilience, and access considerations. Tariff adjustments can alter the cost structure for imported active pharmaceutical ingredients and specialized equipment used in radiotherapy and drug manufacturing, which may prompt manufacturers to revisit sourcing strategies and supplier contracts. These operational shifts often cascade into strategic choices about onshoring components of the supply chain, diversifying supplier bases, and negotiating long-term procurement agreements to mitigate exposure to trade policy volatility.

In addition, tariffs can influence the competitiveness of certain therapeutic modalities by affecting the relative cost of advanced radiotherapy technologies and complex biologic therapies that rely on imported components. For healthcare providers and integrated delivery networks, policy-driven cost pressures may accelerate value-based contracting and require closer collaboration with manufacturers to articulate clinical and economic value. As a result, payors and hospital systems could increase scrutiny on comparative effectiveness and total cost of care when evaluating formulary placement or capital investments.

Finally, the policy environment underscores the importance of proactive regulatory and market access planning. Manufacturers should model tariff scenarios in commercial operations planning, engage with trade and policy experts, and develop contingency strategies that preserve supply continuity and patient access. In parallel, clinical leaders and advocacy groups will need to communicate the clinical necessity of sustaining access to specialized therapies and technologies to minimize unintended disruptions to care delivery.

Deep segmentation-driven insights linking therapeutic modalities, disease staging, molecule classes, treatment lines, and patient age cohorts to practical clinical and commercial implications

Insightful segmentation illuminates distinct clinical and commercial dynamics across treatment modalities, disease stages, therapy lines, molecule classes, and patient age cohorts. When analyzed by treatment type, the landscape encompasses chemotherapy regimens such as ABVD, BEACOPP, and liposomal formulations alongside immunotherapy, radiotherapy approaches that include adaptive planning, involved-field techniques, and proton therapy, and targeted therapies that provide molecularly directed options. Each modality presents unique efficacy and toxicity profiles that inform patient selection and sequencing.

Considering disease stage, early-stage patients categorized into Stage I and Stage II typically follow different therapeutic pathways and survivorship priorities compared with advanced-stage patients in Stage III and Stage IV, where systemic control and durable remission are central objectives. Treatment line segmentation further differentiates clinical strategy, with first-line approaches emphasizing curative intent and second-line and third-line interventions focusing on salvage, bridging to transplant, or palliative control as appropriate.

From a molecule perspective, monoclonal antibodies, including CD30-directed agents such as brentuximab vedotin and next-generation antibodies as well as PD-1 inhibitors represented by agents like nivolumab and pembrolizumab, offer immune-mediated mechanisms that complement or replace cytotoxic therapy in some settings. Small molecules, notably histone deacetylase inhibitors including romidepsin, vorinostat, and next-generation HDAC candidates, provide epigenetic modulation options in select indications. Finally, patient age stratification into adult, geriatric, and pediatric groups influences dosing, treatment tolerance, and long-term monitoring, shaping both clinical trial design and real-world management pathways.

Regional clinical, regulatory, and access dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape localized strategy and patient access pathways

Regional dynamics influence clinical practice patterns, regulatory timelines, and access strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, integrated oncology networks and established clinical pathways facilitate rapid adoption of evidence-based protocols, while reimbursement mechanisms and payer negotiations shape access to high-cost biologics and advanced radiotherapy technologies. Cross-border collaboration and academic centers also play a prominent role in clinical trial enrollment and translational research.

Across Europe, the Middle East and Africa, heterogeneous regulatory frameworks and variable healthcare infrastructure lead to a mosaic of treatment availability and uptake. In many markets, centralized evaluation bodies and health technology assessment processes require robust clinical and economic evidence to support coverage decisions, which impacts launch sequencing and local evidence-generation strategies. Collaboration with regional clinical leaders and patient advocacy organizations is essential to navigate these environments and to align value demonstration with local priorities.

In the Asia-Pacific region, diverse healthcare delivery models coexist with rapidly expanding clinical research capacity and growing emphasis on domestic manufacturing and supply security. Policymakers and providers in this region are increasingly focused on cost-effective adoption of innovative therapies, and strategic partnerships with regional stakeholders can accelerate access while addressing logistical and regulatory challenges. Across all regions, a nuanced understanding of local clinical guidelines, reimbursement landscapes, and infrastructure constraints is crucial for tailoring market entry and access strategies.

Competitive dynamics shaped by clinical portfolios, strategic partnerships, supply chain capabilities, and evidence generation that determine long-term differentiation in Hodgkin lymphoma care

The competitive landscape is characterized by a mix of established oncology players, specialist biotech firms advancing antibody and small-molecule programs, and technology partners focused on radiotherapy hardware and software. Leading organizations are differentiated by their clinical portfolios, capabilities in biomarker-driven development, strategic collaborations, and experience navigating regulatory and payer environments. In addition to product pipelines, companies distinguish themselves through manufacturing capacity for biologics, global supply chain networks, and investments in real-world evidence generation to support long-term value propositions.

Strategic partnerships between pharmaceutical developers and radiation technology providers are increasingly common as multidisciplinary treatment approaches require coordination between systemic therapies and precision radiotherapy. Moreover, companies that invest in patient support programs, digital health tools for treatment monitoring, and clinician education initiatives are better positioned to demonstrate real-world benefits and foster uptake. Intellectual property portfolios, licensing arrangements for next-generation molecules, and early-stage clinical data will also influence competitive positioning as novel agents advance through development.

Ultimately, successful companies combine robust clinical strategies with agile commercial execution, proactive engagement with payers and regulators, and a commitment to evidence generation that captures both clinical outcomes and survivorship metrics. These capabilities enable sustained differentiation in a complex, evolving therapeutic environment.

Operational and strategic recommendations for manufacturers and providers to align clinical development, supply chain resilience, and payer engagement for improved patient outcomes

Industry leaders should pursue an integrated approach that aligns clinical development, commercial strategy, and access planning to ensure therapies reach the patients who will benefit most. First, prioritize clinical programs that incorporate biomarker-driven cohorts and patient-reported outcomes to demonstrate meaningful benefit beyond traditional response metrics. This approach strengthens regulatory and reimbursement conversations and supports adoption by clinicians focused on durable remissions and quality of life.

Second, invest in supply chain resilience by diversifying sourcing and engaging in scenario planning for trade and policy contingencies. Manufacturers should assess the implications of tariffs and logistical constraints and consider regional manufacturing or strategic stockpiles to minimize disruption. Third, foster multidisciplinary collaborations that bring together systemic therapy experts, radiation oncology teams, and supportive care specialists to optimize combination approaches and sequencing in clinical practice.

Fourth, engage early with payers, health technology assessment bodies, and clinician networks to co-develop evidence generation plans that reflect local decision criteria. Fifth, leverage digital tools and patient support programs to improve adherence, monitor adverse events, and capture real-world effectiveness. By executing on these recommendations, organizations can accelerate clinical impact, reinforce value propositions, and improve patient outcomes across diverse care settings.

A rigorous multi-source research methodology combining literature synthesis, expert interviews, and cross-segmentation analysis to derive actionable clinical and commercial insights

This research integrates a multi-source methodology combining systematic literature synthesis, expert interviews, and qualitative analysis of regulatory and clinical practice documents. Primary inputs include peer-reviewed clinical studies, consensus guidelines, and position statements from major oncology societies, which have been synthesized to reflect contemporary clinical practice and therapeutic rationale. Secondary materials encompass clinical trial registries, regulatory approvals, and published real-world studies that provide context for adoption and comparative outcomes.

Additionally, the study incorporates structured interviews with clinicians, clinical trial investigators, and commercial leaders to capture frontline perspectives on treatment selection, sequencing, and access barriers. These expert insights supplement the evidence base and help interpret variability across disease stages, treatment lines, and regional practices. Analytical techniques include cross-segmentation mapping to identify clinical and commercial intersections, scenario analysis for policy impacts, and qualitative synthesis to derive actionable recommendations.

Throughout, methodological rigor was maintained by triangulating findings across multiple sources and transparently documenting assumptions and evidence gaps. Limitations of the analysis are acknowledged where published data are incomplete, and areas recommended for further primary research are identified to support ongoing strategic decision-making.

Synthesis of clinical innovation, operational imperatives, and strategic priorities that collectively define the future direction of Hodgkin lymphoma treatment and access

In conclusion, the Hodgkin lymphoma treatment landscape is characterized by meaningful clinical innovation, evolving standards of care, and complex operational considerations that jointly influence access and therapeutic strategy. Novel immunotherapies and targeted molecules are reshaping the clinical toolkit while advances in radiotherapy delivery expand options for localized disease control with reduced toxicity. These clinical advances must be considered in the context of disease stage, treatment line, molecule class, and patient age to optimize outcomes across diverse populations.

Operational and policy shifts, including tariff changes and regional reimbursement dynamics, underscore the need for proactive planning across manufacturing, supply chain, and payer engagement. Companies and clinical leaders that prioritize evidence generation, multidisciplinary collaboration, and resilient commercialization strategies will be best positioned to translate therapeutic innovation into improved patient care. Finally, ongoing data collection-both in controlled trials and real-world settings-will remain essential to refine practice, support coverage decisions, and ensure sustained access to effective treatments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of PD-1 checkpoint inhibitors into frontline therapy protocols for refractory Hodgkin lymphoma patients
  • 5.2. Adoption of CD30-directed CAR T-cell therapies in relapsed or refractory Hodgkin lymphoma treatment landscapes
  • 5.3. Emerging role of circulating tumor DNA assays to monitor minimal residual disease and guide Hodgkin lymphoma therapy
  • 5.4. Impact of biosimilar brentuximab vedotin entries on pricing dynamics and access to advanced Hodgkin lymphoma therapies
  • 5.5. Increasing utilization of real-world evidence studies to assess long-term safety outcomes in Hodgkin lymphoma survivors
  • 5.6. Development of bispecific antibodies targeting PD-1 and CD30 to enhance immunotherapeutic efficacy in Hodgkin lymphoma
  • 5.7. Expansion of combination regimens merging checkpoint inhibitors with salvage chemotherapy in relapsed Hodgkin lymphoma patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hodgkin Lymphoma Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Abvd Regimen
    • 8.1.2. Beacopp Regimen
    • 8.1.3. Liposomal Formulations
  • 8.2. Immunotherapy
  • 8.3. Radiotherapy
    • 8.3.1. Adaptive Radiotherapy
    • 8.3.2. Involved-Field Radiotherapy
    • 8.3.3. Proton Radiotherapy
  • 8.4. Targeted Therapy

9. Hodgkin Lymphoma Treatment Market, by Disease Stage

  • 9.1. Advanced Stage
    • 9.1.1. Stage III
    • 9.1.2. Stage IV
  • 9.2. Early Stage
    • 9.2.1. Stage I
    • 9.2.2. Stage II

10. Hodgkin Lymphoma Treatment Market, by Treatment Line

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line

11. Hodgkin Lymphoma Treatment Market, by Molecule Type

  • 11.1. Monoclonal Antibodies
    • 11.1.1. Cd30 Directed Antibodies
      • 11.1.1.1. Brentuximab Vedotin
      • 11.1.1.2. Next Generation Antibodies
    • 11.1.2. Pd-1 Inhibitors
      • 11.1.2.1. Nivolumab
      • 11.1.2.2. Pembrolizumab
  • 11.2. Small Molecules
    • 11.2.1. Histone Deacetylase Inhibitors
      • 11.2.1.1. Next Generation Hdac Inhibitors
      • 11.2.1.2. Romidepsin
      • 11.2.1.3. Vorinostat

12. Hodgkin Lymphoma Treatment Market, by Patient Age

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Hodgkin Lymphoma Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hodgkin Lymphoma Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hodgkin Lymphoma Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Takeda Pharmaceutical Company Limited
    • 16.3.2. Bristol-Myers Squibb Company
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. Gilead Sciences, Inc.
    • 16.3.5. Novartis AG
    • 16.3.6. Roche Holding AG
    • 16.3.7. Johnson & Johnson
    • 16.3.8. Pfizer Inc.
    • 16.3.9. Seagen Inc.
    • 16.3.10. Kite Pharma, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. LAT